Comments
Target: ₹1,900
CMP: ₹1,732.25
Sun Pharmaceuticals’ Q1-FY25 result was a miss on revenue while EBITDA/PAT beat our estimates. Overall revenues grew 6 per cent y-o-y to ₹12,500 crore (our est. ₹13,000 crore), led by India/EM delivering 16/11 per cent y-o-y growth offset by muted US growth. API/ROW declined 8/1 per cent y-o-y respectively.
Gross margins expanded 200bps to 78.6 per cent (down 120bps q-o-q). EBITDA grew 11 per cent y-o-y to ₹3,500 crore with margins expanding 130bps y-o-y (+350bps QoQ) at 28.2 per cent (our est. 26.5 per cent). Adjusting for FX loss of ₹50.50 crore, PAT grew 26 per cent y-o-y to ₹2,900 crore (our est ₹2,600 crore) driven by higher other income (+2.5x YoY), lower finance costs (down 24 per cent y-o-y) and lower tax rate of 16.1 per cent (v/s 18.9 per cent in Q1-FY24).
Going forward, management expects specialty business to grow led by growth in key assets (Ilumya, Cequa, Winlevi). It expects R&D expense to be 8-10% of sales in FY25. The increase in R&D spend is largely for specialty portfolio. Moreover, India segment is likely to witness volume-led growth across therapies.
Accordingly, we raise our earnings estimates for FY25/FY26 by 8/4 per cent, factoring DF segment outperforming IPM and superior execution in global specialty sales.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.